FAKTOR-OPTIONSSCHEIN - TG THERAPEUTICS Share Price

Certificat

DE000MG35856

Market Closed - Börse Stuttgart 12:19:37 25/05/2024 am IST
4.96 EUR +5.31% Intraday chart for FAKTOR-OPTIONSSCHEIN - TG THERAPEUTICS
Current month-52.58%
Date Price Change
24/24/24 4.96 +5.31%
23/24/23 4.71 +6.08%
22/24/22 4.44 -13.11%
21/24/21 5.11 -1.54%
20/24/20 5.19 +2.77%

Delayed Quote Börse Stuttgart

Last update May 25, 2024 at 12:19 am IST

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying TG THERAPEUTICS, INC.
Issuer Morgan Stanley
WKN MG3585
ISINDE000MG35856
Date issued 26/04/2024
Strike 25.47 $
Maturity Unlimited
Parity 1.64 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 11.42
Lowest since issue 4.22
Spread 0.02
Spread %0.40%

Company Profile

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Sector
-
More about the company

Ratings for TG Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Consensus: TG Therapeutics, Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
16.71 USD
Average target price
31.5 USD
Spread / Average Target
+88.51%
Consensus